The structural and functional role of myelin fast-migrating cerebrosides: pathological importance in multiple sclerosis

Bibliography

• Rosetti CM, Maggio B, Oliveira RG: Theself-organization of lipids and proteins of myelin at the membrane interface. Molecular factors underlying the microheterogeneity of domain segregation. Biochim. Biophys. Acta 1778(7–8), 1665–1675 (2008)
   Google Scholar
• Norton WT, Autilio LA: The lipid composition of purified bovine brain myelin. J. Neurochem. 13(4), 213–222 (1966)
   Google Scholar
• Fewster ME, Hirono H, Mead JF: Lipid composition of myelin in multiple sclerosis. J. Neurol. 213(2), 119–131 (1976)
   Google Scholar
• Dasgupta S, Levery SB, Hogan EL: 3-O-acetyl-sphingosine-series myelin glycolipids: characterization of novel 3-O-acetyl-sphingosine galactosylceramide. J. Lipid Res. 43(5), 751–761 (2002). n First description of the acetylated derivatives of galactosylceramide
   Google Scholar
• Bennion B, Dasgupta S, Hogan EL, Levery SB: Characterization of novel myelin components 3-O-acetyl-sphingosine galactosylceramides by electrospray ionization Q-TOF MS and MS/CID-MS of Li+ adducts. J. Mass Spectrom. 42(5), 598–620 (2007)
   Google Scholar
• Podbielska M, Dasgupta S, Levery SB et al.: Novel myelin penta- and hexa-acetylgalactosyl- ceramides: structural characterization and immunoreactivity in cerebrospinal fluid. J. Lipid Res. 51(6), 1394–1406 (2010). nn Description of the penta- and hexa-acetyl derivatives of galactosylceramide
   Google Scholar
• Xu L, Anchordoquy TJ: Cholesterol domains in cationic lipid/DNA complexes improve transfection. Biochim. Biophys. Acta 1778(10), 2177–2181 (2008)
   Google Scholar
• Xu Y, Ramu Y, Lu Z: Removal of phosphohead groups of membrane lipids immobilizes voltage sensors of K+ channels. Nature 451(7180), 826–829 (2008)
   Google Scholar
• Yu RK, Ledeen RW: Gangliosides of human, bovine, and rabbit plasma. J. Lipid Res. 13(5), 680–686 (1972)
   Google Scholar
• Wheeler D, Bandaru VV, Calabresi PA, Nath A, Haughey NJ: A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis. Brain 131(Pt 11), 3092–3102 (2008)
   Google Scholar
• Podbielska M, Hogan EL: Molecular and immunogenic features of myelin lipids: incitants or modulators of multiple sclerosis? Mult. Scler. 15(9), 1011–1029 (2009)
   Google Scholar
• Kochetkov NK, Zhukova IG, Glukhoded IS: Sphingoplasmalogens. A new type of sphingolipids. Biochim. Biophys. Acta 70, 716–719 (1963)
   Google Scholar
• Norton WT, Brotz M: New galactolipids of brain: a monoalkyl-monoacyl-glyceryl galactoside and cerebroside fatty acid esters. Biochem. Biophys. Res. Commun. 12, 198–203 (1963)
   Google Scholar
• Kubota M, Taketomi T: Minor glycolipids being less polar than cerebroside in porcine spinal cord. Jpn J. Exp. Med. 44(2), 145–150 (1974)
   Google Scholar
• Nudelman ED, Levery SB, Igarashi Y, Hakomori S: Plasmalopsychosine, a novel plasmal (fatty aldehyde) conjugate of psychosine with cyclic acetal linkage. Isolation and characterization from human brain white matter. J. Biol. Chem. 267(16), 11007–11016 (1992)
   Google Scholar
• Levery SB, Nudelman ED, Hakomori S: Novel modification of glycosphingolipids by long-chain cyclic acetals: isolation and characterization of plasmalocerebroside from human brain. Biochemistry 31(23), 5335–5340 (1992)
   Google Scholar
• Yachida Y, Kashiwagi M, Mikami T et al.: Stereochemical structures of synthesized and natural plasmalogalactosylceramides from equine brain. J. Lipid Res. 39(5), 1039–1045 (1998)
   Google Scholar
• Klenk E, Lohr JP: On the ester cerebrosides of brain. Hoppe Seylers Z. Physiol. Chem. 348(12), 1712–1714 (1967)
   Google Scholar
• Tamai Y: Further study on the faster running glycolipid in brain. Jpn J. Exp. Med. 38(1), 65–73 (1968)
   Google Scholar
• Kishimoto Y, Wajda M, Radin NS: 6-acyl galactosyl ceramides of pig brain: structure and fatty acid composition. J. Lipid Res. 9(1), 27–33 (1968)
   Google Scholar
• Dasgupta S, Everhart MB, Bhat NR, Hogan EL: Neutral monoglycosylceramides in rat brain: occurrence, molecular expression and developmental variation. Dev. Neurosci. 19(2), 152–161 (1997)
   Google Scholar
• Dasgupta S, Bhat NR, Spicer SS, Hogan EL, Furuya S, Hirabayashi Y: Cell-specificexpression of neutral glycosphingolipids in vertebrate brain: immunochemical localization of 3-O-acetyl-sphingosine-series glycolipid(s) in myelin and oligodendrocytes. J. Neurosci. Res. 85(13), 2856–2862 (2007)
   Google Scholar
• Dupree JL, Girault JA, Popko B: Axo–glial interactions regulate the localization of axonal paranodal proteins. J. Cell Biol. 147(6), 1145–1152 (1999)
   Google Scholar
• Suzuki K, Suzuki Y: Globoid cell leucodystrophy (Krabbe’s disease): deficiency of galactocerebroside b-galactosidase. Proc. Natl Acad. Sci. USA 66(2), 302–309 (1970)
   Google Scholar
• Suzuki K, Suzuki Y: Galactosylceramide lipidosis: globoid cell leukodystrophy (Krabbe’s diesease). In: The Metabolic Basis of Inherited Diesease. Stabury JC, Wyngaarden JB, Fredrikson DS, Goldstein JL, Brown MS (Eds). McGraw–Hill, NY, USA, 857–880 (1983)
   Google Scholar
• Svennerholm L, Vanier MT, Mansson JE: Krabbe disease: a galactosylsphingosine (psychosine) lipidosis. J. Lipid Res. 21(1), 53–64 (1980)
   Google Scholar
• Kobayashi T, Shinoda H, Goto I, Yamanaka T, Suzuki Y: Globoid cell leukodystrophy is a generalized galactosylsphingosine (psychosine) storage disease. Biochem. Biophys. Res. Commun. 144(1), 41–46 (1987)
   Google Scholar
• Suzuki K, Suzuki K: The twitcher mouse. A model of human globoid cell leukodystrophy (Krabbe’s disease). Am. J. Pathol. 111(3), 394–397 (1983)
   Google Scholar
• Takahashi H, Igisu H, Suzuki K, Suzuki K: Murine globoid cell leukodystrophy (the twitcher mouse). The presence of characteristic inclusions in the kidney and lymph nodes. Am. J. Pathol. 112(2), 147–154 (1983)
   Google Scholar
• Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG: Multiple sclerosis. N. Engl. J. Med. 343(13), 938–952 (2000)
   Google Scholar
• Becher B, Bechmann I, Greter M: Antigen presentation in autoimmunity and CNS inflammation: how T lymphocytes recognize the brain. J. Mol. Med. 84(7), 532–543 (2006)
   Google Scholar
• Mukherjee S, Soe TT, Maxfield FR: Endocytic sorting of lipid analogues differing solely in the chemistry of their hydrophobic tails. J. Cell Biol. 144(6), 1271–1284 (1999)
   Google Scholar
• Mukherjee S, Maxfield FR: Role of membraneorganization and membrane domains inendocytic lipid trafficking. Traffic(Copenhagen, Denmark) 1(3), 203–211 (2000)
   Google Scholar
• Sugita M, Porcelli SA, Brenner MB: Assembly and retention of CD1b heavy chains in the endoplasmic reticulum. J. Immunol. 159(5), 2358–2365 (1997)
   Google Scholar
• Gadola SD, Zaccai NR, Harlos K et al.: Structure of human CD1b with bound ligands at 2.3 A, a maze for alkyl chains. Nat. Immunol. 3(8), 721–726 (2002)
   Google Scholar
• Batuwangala T, Shepherd D, Gadola SD et al.: The crystal structure of human CD1b with a bound bacterial glycolipid. J. Immunol. 172(4), 2382–2388 (2004)
   Google Scholar
• Moody DB, Ulrichs T, Muhlecker W et al.: CD1c-mediated T-cell recognition of isoprenoid glycolipids in Mycobacterium tuberculosis infection. Nature 404(6780), 884–888 (2000)
   Google Scholar
• Shamshiev A, Gober HJ, Donda A, Mazorra Z, Mori L, De Libero G: Presentation of the same glycolipid by different CD1 molecules. J. Exp. Med. 195(8), 1013–1021 (2002)
   Google Scholar
• van den Elzen P, Garg S, Leon L et al.: Apolipoprotein-mediated pathways of lipid antigen presentation. Nature 437(7060), 906–910 (2005)
   Google Scholar
• Winau F, Schwierzeck V, Hurwitz R et al.: Saposin C is required for lipid presentation by human CD1b. Nat. Immunol. 5(2), 169–174 (2004)
   Google Scholar
• Kang SJ, Cresswell P: Saposins facilitate CD1d-restricted presentation of an exogenous lipid antigen to T cells. Nat. Immunol. 5(2), 175–181 (2004)
   Google Scholar
• Yuan W, Qi X, Tsang P et al.: Saposin B is the dominant saposin that facilitates lipid binding to human CD1d molecules. Proc. Natl Acad. Sci. USA 104(13), 5551–5556 (2007)
   Google Scholar
• Zhou D, Cantu C 3rd, Sagiv Y et al.: Editing of CD1d-bound lipid antigens by endosomal lipid transfer proteins. Science 303(5657), 523–527 (2004)
   Google Scholar
• Bai L, Sagiv Y, Liu Y et al.: Lysosomal recycling terminates CD1d-mediated presentation of short and polyunsaturated variants of the NKT cell lipid antigen aGalCer. Proc. Natl Acad. Sci. USA 106(25), 10254–10259 (2009)
   Google Scholar
• Steinman L: Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 85(3), 299–302 (1996)
   Google Scholar
• Engelhardt B, Ransohoff RM: The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol. 26(9), 485–495 (2005)
   Google Scholar
• Alt C, Laschinger M, Engelhardt B: Functional expression of the lymphoid chemokines CCL19 (ELC) and CCL 21 (SLC) at the blood–brain barrier suggests their involvement in G-proteindependent lymphocyte recruitment into the central nervous system during experimental autoimmune encephalomyelitis. Eur. J. Immunol. 32(8), 2133–2144 (2002)
   Google Scholar
• Columba-Cabezas S, Serafini B, Ambrosini E, Aloisi F: Lymphoid chemokines CCL19 and CCL21 are expressed in the central nervous system during experimental autoimmune encephalomyelitis: implications for the maintenance of chronic neuroinflammation. Brain Pathol. 13(1), 38–51 (2003)
   Google Scholar
• Greter M, Heppner FL, Lemos MP et al.: Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat. Med. 11(3), 328–334 (2005)
   Google Scholar
• Racke MK, Scott DE, Quigley L et al.: Distinct roles for B7–1 (CD-80) and B7–2 (CD-86) in the initiation of experimental allergic encephalomyelitis. J. Clin. Invest.96(5), 2195–2203 (1995)
   Google Scholar
• Weinberg AD, Wegmann KW, Funatake C, Whitham RH: Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. J. Immunol. 162(3), 1818–1826 (1999)
   Google Scholar
• Frohman EM, Filippi M, Stuve O et al.: Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions. Arch. Neurol. 62(9), 1345–1356 (2005)
   Google Scholar
• Chekhonin VP, Semenova AV, Gurina OI, Dmitrieva TB: Myelin oligodendrogliocyte glycoprotein: the structure, functions, role in pathogenesis of demyelinating disorders. Biomed. Khim. 49(5), 411–423 (2003)
   Google Scholar
• Quarles RH: Myelin-associated glycoprotein (MAG): past, present and beyond. J. Neurochem. 100(6), 1431–1448 (2007)
   Google Scholar
• Jaskiewicz E: Epitopes on myelin proteins recognized by autoantibodies present in multiple sclerosis patients. Postepy Hig. Med. Dosw. (Online) 58, 472–482 (2004)
   Google Scholar
• Johns TG, Bernard CC: The structure and function of myelin oligodendrocyte glycoprotein. J. Neurochem. 72(1), 1–9 (1999)
   Google Scholar
• Meinl E, Hohlfeld R: Immunopathogenesis of multiple sclerosis: MBP and beyond. Clin.Exp. Immunol. 128(3), 395–397 (2002)
   Google Scholar
• Tzakos AG, Troganis A, Theodorou V et al.: Structure and function of the myelin proteins: current status and perspectives in relation to multiple sclerosis. Curr. Med. Chem. 12(13), 1569–1587 (2005)
   Google Scholar
• Sobel RA, Greer JM, Kuchroo VK: Minireview: autoimmune responses to myelin proteolipid protein. Neurochem. Res. 19(8), 915–921 (1994)
   Google Scholar
• Musse AA, Harauz G: Molecular ‘negativity’ may underlie multiple sclerosis: role of the myelin basic protein family in the pathogenesis of MS. Int. Rev. Neurobiol. 79, 149–172 (2007)
   Google Scholar
• Quarles RH: Myelin sheaths: glycoproteins involved in their formation, maintenance and degeneration. Cell. Mol. Life Sci. 59(11), 1851–1871 (2002)
   Google Scholar
• Menge T, Lalive PH, von Budingen HC, Cree B, Hauser SL, Genain CP: Antibody responses against galactocerebroside are potential stage-specific biomarkers in multiple sclerosis. J. Allergy Clin. Immunol. 116(2), 453–459 (2005)
   Google Scholar
• Mata S, Lolli F, Soderstrom M, Pinto F, Link H: Multiple sclerosis is associated with enhanced B cell responses to the ganglioside GD1a. Mult. Scler. 5(6), 379–388 (1999)
   Google Scholar
• Sadatipour BT, Greer JM, Pender MP: Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis. Ann. Neurol.44(6), 980–983 (1998)
   Google Scholar
• Acarin N, Rio J, Fernandez AL et al.: Different antiganglioside antibody pattern between relapsing-remitting and progressive multiple sclerosis. Acta Neurol. Scand. 93(2–3), 99–103 (1996)
   Google Scholar
• Ilyas AA, Chen ZW, Cook SD: Antibodies to sulfatide in cerebrospinal fluid of patients with multiple sclerosis. J. Neuroimmunol. 139(1–2), 76–80 (2003)
   Google Scholar
• Ryberg B: Multiple specificities of antibrain antibodies in multiple sclerosis and chronic myelopathy. J. Neurol. Sci. 38(3), 357–382 (1978)
   Google Scholar
• Sugiyama Y, Yamamoto T: Characterization of serum anti-phospholipid antibodies in patients with multiple sclerosis. Tohoku J. Exp. Med. 178(3), 203–215 (1996)
   Google Scholar
• Kanter JL, Narayana S, Ho PP et al.: Lipid microarrays identify key mediators of autoimmune brain inflammation. Nat. Med. 12(1), 138–143 (2006). nn Identification of lipid and oxidized lipid antigens reactive with IgG in multiple sclerosis cerebrospinal fluid
   Google Scholar
• Zheng W, Kollmeyer J, Symolon H et al.: Ceramides and other bioactive sphingolipid backbones in health and disease: lipidomic analysis, metabolism and roles in membrane structure, dynamics, signaling and autophagy. Biochim. Biophys. Acta 1758(12), 1864–1884 (2006)
   Google Scholar
• Taha TA, Mullen TD, Obeid LM: A house divided: ceramide, sphingosine, and sphingosine-1-phosphate in programmed cell death. Biochim. Biophys. Acta 1758(12), 2027–2036 (2006)
   Google Scholar
• Stoffel W, Bosio A: Myelin glycolipids and their functions. Curr. Opin. Neurobiol. 7(5), 654–661 (1997)
   Google Scholar
• Schenck M, Carpinteiro A, Grassme H, Lang F, Gulbins E: Ceramide: physiological and pathophysiological aspects. Arch. Biochem. Biophys. 462(2), 171–175 (2007)
   Google Scholar
• Obeid LM, Hannun YA: Ceramide: a stress signal and mediator of growth suppression and apoptosis. J. Cell. Biochem. 58(2), 191–198 (1995)
   Google Scholar
• Pettus BJ, Chalfant CE, Hannun YA: Sphingolipids in inflammation: roles and implications. Curr. Mol. Med. 4(4), 405–418 (2004)
   Google Scholar
• Merrill AH Jr, Schmelz EM, Dillehay DL et al.: Sphingolipids – the enigmatic lipid class: biochemistry, physiology, and pathophysiology. Toxicol. Appl. Pharmacol. 142(1), 208–225 (1997)
   Google Scholar
• Kronke M: Involvement of sphingomyelinases in TNF signaling pathways. Chem. Phys. Lipids 102(1–2), 157–166 (1999)
   Google Scholar
• Kolesnick RN: Sphingomyelin and derivatives as cellular signals. Prog. Lipid Res. 30(1), 1–38 (1991)
   Google Scholar
• Hannun YA, Obeid LM, Wolff RA: The novel second messenger ceramide: identification, mechanism of action, and cellular activity. Adv. Lipid Res. 25, 43–64 (1993)
   Google Scholar
• Wirguin I, Brenner T, Steinitz M,Abramsky O: In vitro synthesis of antibodies to myelin antigens by Epstein–Barr virus-transformed B lymphocytes from patients with neurologic disorders. J. Neurol.Sci. 104(1), 92–96 (1991)
   Google Scholar
• Richert JR, Robinson ED, Reuben‑Burnside CA et al.: Measles virus-specific human T cell clones: studies of alloreactivity and antigenic cross-reactivity. J. Neuroimmunol. 19(1–2), 59–68 (1988)
   Google Scholar
• Mameli G, Astone V, Arru G et al.: Brains and peripheral blood mononuclear cells of multiple sclerosis (MS) patients hyperexpress MS-associated retrovirus/HERV-W endogenous retrovirus, but not human herpesvirus 6. J. Gen. Virol. 88(Pt 1), 264–274 (2007)
   Google Scholar
• Lunemann JD, Edwards N, Muraro PA et al.: Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain 129(Pt 6), 1493–1506 (2006)
   Google Scholar
• Serafini B, Rosicarelli B, Franciotta D et al.: Dysregulated Epstein–Barr virus infection in the multiple sclerosis brain. J. Exp. Med. 204(12), 2899–2912 (2007)
   Google Scholar
• Vartdal F, Vandvik B, Norrby E: Viral and bacterial antibody responses in multiple sclerosis. Ann. Neurol. 8(3), 248–255 (1980)
   Google Scholar
• Vartdal F, Vandvik B: Multiple sclerosis: subclasses of intrathecally synthesized IgG and measles and varicella zoster virus IgG antibodies. Clin. Exp. Immunol. 54(3), 641–647 (1983)
   Google Scholar
• Salmi A, Reunanen M, Ilonen J, Panelius M: Intrathecal antibody synthesis to virus antigens in multiple sclerosis. Clin. Exp. Immunol. 52(2), 241–249 (1983)
   Google Scholar
• Burgoon MP, Williamson RA, Owens GP et al.: Cloning the antibody response in humans with inflammatory CNS disease: isolation of measles virus-specific antibodies from phage display libraries of a subacute sclerosing panencephalitis brain. J. Neuroimmunol. 94(1–2), 204–211 (1999)
   Google Scholar
• Cremer NE, Johnson KP, Fein G, Likosky WH: Comprehensive viral immunology of multiple sclerosis. II. Analysis of serum and CSF antibodies by standard serologic methods. Arch. Neurol. 37(10), 610–615 (1980)
   Google Scholar
• von Herrath MG, Fujinami RS, Whitton JL: Microorganisms and autoimmunity: making the barren field fertile? Nat. Rev. Microbiol. 1(2), 151–157 (2003)
   Google Scholar
• Wucherpfennig KW: Mechanisms for the induction of autoimmunity by infectious agents. J. Clin. Invest. 108(8), 1097–1104 (2001)
   Google Scholar
• Oldstone MB: Molecular mimicry, microbial infection, and autoimmune disease: evolution of the concept. Curr. Top. Microbiol. Immunol. 296, 1–17 (2005). n Early exposition of the possible role ofmolecular mimicry in the relationship of infection with autoimmune disease in man
   Google Scholar
• van Noort JM, Bajramovic JJ, Plomp AC, van Stipdonk MJ: Mistaken self, a novel model that links microbial infections with myelindirected autoimmunity in multiple sclerosis. J. Neuroimmunol. 105(1), 46–57 (2000)
   Google Scholar
• Tejada-Simon MV, Zang YC, Hong J, Rivera VM, Zhang JZ: Cross-reactivity with myelin basic protein and human herpesvirus-6 in multiple sclerosis. Ann. Neurol. 53(2), 189–197 (2003)
   Google Scholar
• Sospedra M, Martin R: Molecular mimicry in multiple sclerosis. Autoimmunity 39(1), 3–8 (2006)
   Google Scholar
• McCoy L, Tsunoda I, Fujinami RS: Multiplesclerosis and virus induced immune responses: autoimmunity can be primed by molecular mimicry and augmented by bystander activation. Autoimmunity 39(1), 9–19 (2006)
   Google Scholar
• Barnett LA, Fujinami RS: Molecular mimicry: a mechanism for autoimmune injury. FASEB J. 6(3), 840–844 (1992)
   Google Scholar
• Oldstone MB: Molecular mimicry and immune-mediated diseases. FASEB J. 12(13), 1255–1265 (1998)
   Google Scholar
• McLean BN, Luxton RW, Thompson EJ: A study of immunoglobulin G in the cerebrospinal fluid of 1007 patients with suspected neurological disease using isoelectric focusing and the Log IgG-Index.A comparison and diagnostic applications. Brain 113(Pt 5), 1269–1289 (1990)
   Google Scholar
• Correale J, de los Milagros Bassani Molinas M: Oligoclonal bands and antibody responses in multiple sclerosis. J. Neurol. 249(4), 375–389 (2002)
   Google Scholar
• Antel J, Bar-Or A: Roles of immunoglobulins and B cells in multiple sclerosis: from pathogenesis to treatment. J. Neuroimmunol. 180(1–2), 3–8 (2006). n Recent review of the possible roles of B cells and immunoglobulins in multiple sclerosis
   Google Scholar
• Melendez-Vasquez C, Redford J, Choudhary PP et al.: Immunological investigation of chronic inflammatory demyelinating polyradiculoneuropathy. J. Neuroimmunol. 73(1–2), 124–134 (1997)
   Google Scholar
• Goodyear CS, O’Hanlon GM, Plomp JJ et al.: Monoclonal antibodies raised against Guillain–Barre syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations. J. Clin. Invest. 104(6), 697–708 (1999)
   Google Scholar
• Yuki N: Molecular mimicry between gangliosides and lipopolysaccharides of Campylobacter jejuni isolated from patients with Guillain–Barre syndrome and Miller Fisher syndrome. J. Infect. Dis. 176(Suppl. 2), S150–S153 (1997)
   Google Scholar
• Yuki N, Miyatake T: Guillain–Barre syndrome and Fisher’s syndrome following Campylobacter jejuni infection. Ann. NY Acad. Sci. 845, 330–340 (1998)
   Google Scholar
• Prendergast MM, Willison HJ, Moran AP: Human monoclonal immunoglobulin M antibodies to ganglioside GM1 show diverse cross-reactivities with lipopolysaccharides of Campylobacter jejuni strains associated with Guillain–Barre syndrome. Infect. Immun. 67(7), 3698–3701 (1999). n Good example of the support for glycolipid‑based molecular mimicry to Campylobacter jejuni bacterial infection and autoimmune disease, the Guillain–Barré syndrome, in the human peripheral nervous system
   Google Scholar
• Sack DA, Lastovica AJ, Chang SH, Pazzaglia G: Microtiter assay for detecting Campylobacter spp. and Helicobacter pylori with surface gangliosides which bind cholera toxin. J. Clin. Microbiol. 36(7), 2043–2045 (1998)
   Google Scholar
• Mori M, Kuwabara S, Miyake M et al.: Haemophilus influenzae has a GM1ganglioside-like structure and elicits Guillain–Barre syndrome. Neurology 52(6), 1282–1284 (1999)
   Google Scholar
• Yu RK, Ariga T: The role of glycosphingolipids in neurological disorders. Mechanisms of immune action. Ann. NY Acad. Sci. 845, 285–306 (1998)
   Google Scholar
• Katzenellenbogen E, Kocharova NA, Korzeniowska-Kowal A et al.: Immunochemical studies of the lipopolysaccharides of Hafnia alvei PCM 1219 and other strains with the O-antigens containing d-glucose 1-phosphate and 2-deoxy-2-[(R)-3- hydroxybutyramido]-d-glucose. Arch. Immunol. Ther. Exp. (Warsz.) 56(5), 347–352 (2008)
   Google Scholar
• Parolis H, Parolis LA, Olivieri G: Structural studies on the Shigella-likeEscherichia coli O121 O-specific polysaccharide. Carbohydr. Res. 303(3), 319–325 (1997)
   Google Scholar
• Ali T, Weintraub A, Widmalm G: Structural determination of the O-antigenic polysaccharide from the Shiga toxinproducing Escherichia coli O171. Carbohydr. Res. 341(11), 1878–1883 (2006)
   Google Scholar
• Sidorczyk Z, Toukach FV, Zych K et al.: Structural and serological relatedness of the O-antigens of Proteus penneri 1 and 4 from a novel Proteus serogroup O72. Eur. J. Biochem. 269(1), 358–363 (2002)
   Google Scholar
• Kubler-Kielb J, Vinogradov E, Chu C, Schneerson R: O-Acetylation in the O-specific polysaccharide isolated from Shigella flexneri serotype 2a. Carbohydr. Res. 342(3–4), 643–647 (2007)
   Google Scholar
• Schroder NW, Schombel U, Heine H, Gobel UB, Zahringer U, Schumann RR: Acylated cholesteryl galactoside as a novel immunogenic motif in Borrelia burgdorferi sensu stricto. J. Biol. Chem. 278(36), 33645–33653 (2003)
   Google Scholar
• Yildirim HH, Li J, Richards JC, Hood DW, Moxon ER, Schweda EK: Complex O-acetylation in non-typeable Haemophilus influenzae lipopolysaccharide: evidence for a novel site of O-acetylation. Carbohydr. Res. 340(17), 2598–2611 (2005)
   Google Scholar
• MacLean LL, Webb AC, Perry MB: Structural elucidation of the O-antigenic polysaccharide from enterohemorrhagic (EHEC) Escherichia coli O48:H21. Carbohydr. Res. 341(15), 2543–2549 (2006)
   Google Scholar
• Compston A: Complexity and heterogeneity in demyelinating disease. Brain 130(Pt 5), 1178–1180 (2007)
   Google Scholar
• Lassmann H, Bruck W, Lucchinetti C: Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol. Med. 7(3), 115–121 (2001)
   Google Scholar
• Walker LS, Abbas AK: The enemy within: keeping self-reactive T cells at bay in the periphery. Nat. Rev. Immunol. 2(1), 11–19 (2002)
   Google Scholar
• Ben-Nun A, Wekerle H, Cohen IR: Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein.Nature 292(5818), 60–61 (1981)
   Google Scholar
• Wolf SD, Dittel BN, Hardardottir F, Janeway CA Jr: Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J. Exp. Med. 184(6), 2271–2278 (1996)
   Google Scholar
• Zhang B, Yamamura T, Kondo T, Fujiwara M, Tabira T: Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J. Exp. Med. 186(10), 1677–1687 (1997)
   Google Scholar
• Van Kaer L: Natural killer T cells as targets for immunotherapy of autoimmune diseases. Immunol. Cell Biol. 82(3), 315–322 (2004)
   Google Scholar
• Linsen L, Somers V, Stinissen P: Immunoregulation of autoimmunity by natural killer T cells. Hum. Immunol. 66(12), 1193–1202 (2005)
   Google Scholar
• Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L: NKT cells: what’s in a name? Nat. Rev. Immunol. 4(3), 231–237 (2004)
   Google Scholar
• O’Keeffe J, Gately CM, Counihan T et al.: T-cells expressing natural killer (NK) receptors are altered in multiple sclerosis and responses to a-galactosylceramide are impaired. J. Neurol. Sci. 275(1–2), 22–28 (2008)
   Google Scholar
• Doherty DG, Norris S, Madrigal-Estebas L et al.: The human liver contains multiple populations of NK cells, T cells, and CD3+CD56+ natural T cells with distinct cytotoxic activities and Th1, Th2, and Th0 cytokine secretion patterns. J. Immunol. 163(4), 2314–2321 (1999)
   Google Scholar
• Snyder MR, Nakajima T, Leibson PJ, Weyand CM, Goronzy JJ: Stimulatory killer Ig-like receptors modulate T cell activation through DAP12-dependent and DAP12-independent mechanisms. J. Immunol. 173(6), 3725–3731 (2004)
   Google Scholar
• Kronenberg M: Toward an understanding of NKT cell biology: progress and paradoxes. Annu. Rev. Immunol. 23, 877–900 (2005)
   Google Scholar
• Carding SR, Egan PJ: gd T cells: functional plasticity and heterogeneity. Nat. Rev. Immunol. 2(5), 336–345 (2002)
   Google Scholar
• Zajonc DM, Elsliger MA, Teyton L, Wilson IA: Crystal structure of CD1a in complex with a sulfatide self antigen at a resolution of 2.15 A. Nat. Immunol. 4(8), 808–815 (2003)
   Google Scholar
• Zajonc DM, Crispin MD, Bowden TA et al.: Molecular mechanism of lipopeptide presentation by CD1a. Immunity 22(2), 209–219 (2005)
   Google Scholar
• Zajonc DM, Cantu C 3rd, Mattner J et al.: Structure and function of a potent agonist for the semi-invariant natural killer T cell receptor. Nat. Immunol. 6(8), 810–818 (2005)
   Google Scholar
• Koch M, Stronge VS, Shepherd D et al.: The crystal structure of human CD1d with and without a-galactosylceramide. Nat. Immunol. 6(8), 819–826 (2005)
   Google Scholar
• Giabbai B, Sidobre S, Crispin MD et al.: Crystal structure of mouse CD1d bound to the self ligand phosphatidylcholine: a molecular basis for NKT cell activation. J. Immunol. 175(2), 977–984 (2005)
   Google Scholar
• Moody DB, Zajonc DM, Wilson IA: Anatomy of CD1-lipid antigen complexes. Nat. Rev. Immunol. 5(5), 387–399 (2005)
   Google Scholar
• Miyamoto K, Miyake S, Yamamura T: A synthetic glycolipid prevents autoimmuneencephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 413(6855),531–534 (2001)
   Google Scholar
• Parekh VV, Singh AK, Wilson MT et al.: Quantitative and qualitative differences in the in vivo response of NKT cells to distinct a- and b-anomeric glycolipids. J. Immunol. 173(6), 3693–3706 (2004)
   Google Scholar
• Ortaldo JR, Young HA, Winkler-Pickett RT, Bere EW Jr, Murphy WJ, Wiltrout RH: Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by theuse of distinct TCR-binding ceramides. J. Immunol. 172(2), 943–953 (2004)
   Google Scholar
• Godfrey DI, Kronenberg M: Going both ways: immune regulation via CD1ddependent NKT cells. J. Clin. Invest. 114(10), 1379–1388 (2004). n Recent review of the role of glycolipidreactive invariant natural killer T cells in the regulation of immune responsiveness
   Google Scholar
• Wilson SB, Delovitch TL: Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity. Nat. Rev. Immunol. 3(3), 211–222 (2003)
   Google Scholar
• Illes Z, Kondo T, Newcombe J, Oka N, Tabira T, Yamamura T: Differential expression of NK T cell V a 24J a Q invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. J. Immunol. 164(8), 4375–4381 (2000)
   Google Scholar
• Demoulins T, Gachelin G, Bequet D, Dormont D: A biased Va24+ T-cell repertoire leads to circulating NKT-cell defects in a multiple sclerosis patient at the onset of his disease. Immunol. Lett. 90(2–3), 223–228 (2003)
   Google Scholar
• Araki M, Kondo T, Gumperz JE, Brenner MB, Miyake S, Yamamura T: Th2bias of CD4+ NKT cells derived from multiple sclerosis in remission. Int. Immunol. 15(2), 279–288 (2003)
   Google Scholar
• D’Andrea A, Goux D, De Lalla C et al.: Neonatal invariant Va24+ NKT lymphocytes are activated memory cells. Eur. J. Immunol. 30(6), 1544–1550 (2000)
   Google Scholar
• van Der Vliet HJ, Nishi N, de Gruijl TD et al.: Human natural killer T cells acquire a memory-activated phenotype before birth. Blood 95(7), 2440–2442 (2000)
   Google Scholar
• Miyake S, Yamamura T: Therapeutic potential of glycolipid ligands for natural killer (NK) T cells in the suppression of autoimmune diseases. Curr. Drug Targets Immune Endocr. Metabol. Disord. 5(3), 315–322 (2005)
   Google Scholar
• Mars LT, Gautron AS, Novak J et al.: Invariant NKT cells regulate experimental autoimmune encephalomyelitis and infiltrate the central nervous system in a CD1d-independent manner. J. Immunol. 181(4), 2321–2329 (2008)
   Google Scholar
• Winkler-Pickett R, Young HA, Cherry JM et al.: In vivo regulation of experimental autoimmune encephalomyelitis by NK cells: alteration of primary adaptive responses. J. Immunol. 180(7), 4495–4506 (2008)
   Google Scholar
• Singh AK, Wilson MT, Hong S et al.: Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J. Exp. Med. 194(12), 1801–1811 (2001)
   Google Scholar
• Pal E, Tabira T, Kawano T, Taniguchi M, Miyake S, Yamamura T: Costimulationdependent modulation of experimental autoimmune encephalomyelitis by ligand stimulation of V a 14 NK T cells. J. Immunol. 166(1), 662–668 (2001)
   Google Scholar
• Jahng AW, Maricic I, Pedersen B et al.: Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J. Exp. Med. 194(12), 1789–1799 (2001)
   Google Scholar
• Furlan R, Bergami A, Cantarella D et al.: Activation of invariant NKT cells by aGalCeradministration protects mice from MOG35– 55-induced EAE: critical roles for administration route and IFN-g. Eur. J. Immunol. 33(7), 1830–1838 (2003)
   Google Scholar
• Kinjo Y, Wu D, Kim G et al.: Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 434(7032), 520–525 (2005)
   Google Scholar
• Kinjo Y, Tupin E, Wu D et al.: Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nat. Immunol. 7(9), 978–986 (2006)
   Google Scholar
• Zhou D, Mattner J, Cantu C 3rd et al.: Lysosomal glycosphingolipid recognition by NKT cells. Science 306(5702), 1786–1789 (2004)
   Google Scholar
• Jahng A, Maricic I, Aguilera C, Cardell S,Halder RC, Kumar V: Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. J. Exp. Med. 199(7), 947–957 (2004)
   Google Scholar
• Wu DY, Segal NH, Sidobre S, Kronenberg M, Chapman PB: Cross-presentation of disialoganglioside GD3 to natural killer T cells. J. Exp. Med. 198(1), 173–181 (2003)
   Google Scholar
• Shamshiev A, Donda A, Carena I, Mori L, Kappos L, De Libero G: Self glycolipids as T-cell autoantigens. Eur. J. Immunol. 29(5), 1667–1675 (1999)
   Google Scholar
• Shamshiev A, Donda A, Prigozy TI et al.: The ab T cell response to self-glycolipids shows a novel mechanism of CD1b loading and a requirement for complex oligosaccharides. Immunity 13(2), 255–264 (2000)
   Google Scholar
• Zajonc DM, Maricic I, Wu D et al.: Structural basis for CD1d presentation of a sulfatide derived from myelin and its implications for autoimmunity. J. Exp. Med. 202(11), 1517–1526 (2005)
   Google Scholar
• Gumperz JE, Roy C, Makowska A et al.: Murine CD1d-restricted T cell recognition of cellular lipids. Immunity 12(2), 211–221 (2000)
   Google Scholar
• Sospedra M, Martin R: Immunology of multiple sclerosis. Annu. Rev. Immunol. 23,683–747 (2005)
   Google Scholar
• Prat A, Antel J: Pathogenesis of multiple sclerosis. Curr. Opin. Neurol. 18(3), 225–230 (2005)
   Google Scholar
• Battistini L, Fischer FR, Raine CS, Brosnan CF: CD1b is expressed in multiple sclerosis lesions. J. Neuroimmunol. 67(2),145–151 (1996)
   Google Scholar
• De Libero G, Macdonald HR, Dellabona P: T cell recognition of lipids: quo vadis? Nat. Immunol. 8(3), 223–227 (2007)
   Google Scholar
• Yu KO, Im JS, Molano A et al.: Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of a-galactosylceramides. Proc. Natl Acad. Sci. USA 102(9), 3383–3388 (2005)
   Google Scholar
• Halder RC, Jahng A, Maricic I, Kumar V: Mini review: immune response to myelin-derived sulfatide and CNS-demyelination. Neurochem. Res. 32(2), 257–262 (2007)
   Google Scholar
• Kolodny E, De Gasper R, GamaSosa MA, Weinreb HJ, Herbert J: Antisulfatide immunoglobulin G is elevated in the serum of multiple sclerosis patients. Ann. Neurol. 38, 340 (1995)
   Google Scholar
• Kirschning E, Rutter G, Uhlig H, Dernick R: A sulfatide-reactive human monoclonal antibody obtained from a multiple sclerosis patient selectively binds to the surface of oligodendrocytes. J. Neuroimmunol. 56(2), 191–200 (1995)
   Google Scholar
• Dyer CA, Benjamins JA: Galactocerebroside and sulfatide independently mediate Ca2+ responses in oligodendrocytes. J. Neurosci. Res. 30(4), 699–711 (1991)
   Google Scholar
• Rosenbluth J, Moon D: Dysmyelination induced in vitro by IgM antisulfatide and antigalactocerebroside monoclonal antibodies. J. Neurosci. Res. 71(1), 104–109 (2003)
   Google Scholar
• Bansal R, Pfeiffer SE: Reversible inhibition of oligodendrocyte progenitor differentiation by a monoclonal antibody against surface galactolipids. Proc. Natl Acad. Sci. USA 86(16), 6181–6185 (1989)
   Google Scholar
• Dupree JL, Coetzee T, Suzuki K, Popko B: Myelin abnormalities in mice deficient in galactocerebroside and sulfatide. J. Neurocytol. 27(9), 649–659 (1998)
   Google Scholar
• Marcus J, Popko B: Galactolipids are molecular determinants of myelin development and axo-glial organization. Biochim. Biophys. Acta 1573(3), 406–413 (2002)
   Google Scholar
• Ishibashi T, Dupree JL, Ikenaka K et al.: A myelin galactolipid, sulfatide, is essential for maintenance of ion channels on myelinated axon but not essential for initial cluster formation. J. Neurosci. 22(15),6507–6514 (2002)
   Google Scholar
• Marcus J, Honigbaum S, Shroff S, Honke K, Rosenbluth J, Dupree JL: Sulfatide is essential for the maintenance of CNS myelin and axon structure. Glia 53(4), 372–381 (2006)
   Google Scholar
• Jeon SB, Yoon HJ, Park SH, Kim IH,Park EJ: Sulfatide, a major lipid component of myelin sheath, activates inflammatory responses as an endogenous stimulator in brain-resident immune cells. J. Immunol. 181(11), 8077–8087 (2008)
   Google Scholar
• Stevens A, Weller M, Wietholter H: CSF and serum ganglioside antibody patterns in MS. Acta Neurol. Scand. 86(5), 485–489 (1992)
   Google Scholar
• Pender MP, Csurhes PA, Wolfe NP et al.: Increased circulating T cell reactivity to GM3 and GQ1b gangliosides in primary progressive multiple sclerosis. J. Clin. Neurosci. 10(1), 63–66 (2003)
   Google Scholar
• Valentino P, Labate A, Nistico R et al.: Anti-GM1 antibodies are not associated with cerebral atrophy in patients with multiple sclerosis. Mult. Scler. 15(1), 114–115 (2009)
   Google Scholar
• Giovannoni G, Morris PR, Keir G: Circulating antiganglioside antibodies are not associated with the development of progressive disease or cerebral atrophy in patients with multiple sclerosis. Ann. Neurol. 47(5), 684–685 (2000)
   Google Scholar
• Ruf P, Jager M, Ellwart J, Wosch S, Kusterer E, Lindhofer H: Two new trifunctional antibodies for the therapy of human malignant melanoma. Int. J. Cancer 108(5), 725–732 (2004)
   Google Scholar
• Bjartmar C, Kinkel RP, Kidd G, Rudick RA, Trapp BD: Axonal loss in normal-appearing white matter in a patient with acute MS. Neurology 57(7), 1248–1252 (2001)
   Google Scholar
• Bjartmar C, Trapp BD: Axonal degeneration and progressive neurologic disability in multiple sclerosis. Neurotox. Res. 5(1–2), 157–164 (2003)
   Google Scholar
• Zaprianova E, Deleva D, Ilinov P et al.: Serum ganglioside patterns in multiple sclerosis. Neurochem. Res. 26(2), 95–100 (2001)
   Google Scholar
• Roussel V, Yi F, Jauberteau MO et al.: Prevalence and clinical significance of anti-phospholipid antibodies in multiple sclerosis: a study of 89 patients. J. Autoimmun. 14(3), 259–265 (2000)
   Google Scholar
• Cordoliani MA, Michon-Pasturel U, Rerat K et al.: Multiple sclerosis and antiphospholipid antibodies: study of 62 consecutive patients. Rev. Med. Interne 19(9), 635–639 (1998)
   Google Scholar
• D’Olhaberriague L, Levine SR, Salowich‑Palm L et al.: Specificity, isotype, and titer distribution of anticardiolipin antibodies in CNS diseases. Neurology 51(5), 1376–1380 (1998)
   Google Scholar
• Tourbah A, Clapin A, Gout O et al.: Systemic autoimmune features and multiple sclerosis: a 5‑year follow-up study. Arch. Neurol. 55(4), 517–521 (1998)
   Google Scholar
• Lolli F, Mata S, Baruffi MC, Amaducci L:Cerebrospinal fluid anti-cardiolipinantibodies in neurological diseases. ClinImmunol. Immunopathol. 59(2), 314–321(1991)
   Google Scholar
• Chaleomchan W, Hemachudha T, Sakulramrung R, Deesomchok U:Anticardiolipin antibodies in patients with rabies vaccination induced neurological complications and other neurological diseases. J. Neurol. Sci. 96(2–3), 143–151 (1990)
   Google Scholar
• Marchiori PE, Dos Reis M, Quevedo ME et al.: Cerebrospinal fluid and serum antiphospholipid antibodies in multiple sclerosis, Guillain–Barre syndrome and systemic lupus erythematosus. Arq. Neuropsiquiatr. 48(4), 465–468 (1990)
   Google Scholar
• Karussis D, Leker RR, Ashkenazi A, Abramsky O: A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity? Ann. Neurol. 44(4), 629–634 (1998)
   Google Scholar
• Tartaglia MC, Narayanan S, De Stefano N et al.: Choline is increased in pre-lesional normal appearing white matter in multiple sclerosis. J. Neurol. 249(10), 1382–1390 (2002)
   Google Scholar
• Qin J, Goswami R, Balabanov R, Dawson G: Oxidized phosphatidylcholine is a marker for neuroinflammation in multiple sclerosis brain. J. Neurosci. Res. 85(5), 977–984 (2007)
   Google Scholar
• Woodruff RH, Franklin RJ: Demyelination and remyelination of the caudal cerebellar peduncle of adult rats following stereotaxic injections of lysolecithin, ethidium bromide, and complement/anti-galactocerebroside: a comparative study. Glia 25(3), 216–228 (1999)
   Google Scholar
• Villar LM, Sadaba MC, Roldan E et al.: Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J. Clin. Invest. 115(1), 187–194 (2005). 200 O’Keeffe J, Doherty DG, Kenna T et al.: Diverse populations of T cells with NK cell receptors accumulate in the human intestine in health and in colorectal cancer. Eur. J. Immunol. 34(8), 2110–2119 (2004)
   Google Scholar
• Kenna T, Golden-Mason L, Porcelli SA et al.: NKT cells from normal and tumor-bearing human livers are phenotypically and functionally distinct from murine NKT cells. J. Immunol. 171(4), 1775–1779 (2003)
   Google Scholar
• O’Keeffe J, Gately CM, Counihan T et al.: T-cells expressing natural killer (NK) receptors are altered in multiple sclerosis and responses to a-galactosylceramide are impaired.
   Google Scholar
• J. Neurol. Sci. 275(1–2), 22–28 (2008)
   Google Scholar
• Pittet MJ, Speiser DE, Valmori D, Cerottini JC, Romero P: Cutting edge: cytolytic effector function in human circulating CD8+ T cells closely correlates with CD56 surface expression. J. Immunol. 164(3), 1148–1152 (2000)
   Google Scholar
• Loza MJ, Metelitsa LS, Perussia B: NKT and T cells: coordinate regulation of NK-like phenotype and cytokine production. Eur. J. Immunol. 32(12), 3453–3462 (2002)
   Google Scholar
• Exley M, Porcelli S, Furman M, Garcia J, Balk S: CD161 (NKR-P1A) costimulation of CD1d-dependent activation of human T cells expressing invariant V a 24 J a Q T cell receptor a chains. J. Exp. Med. 188(5), 867–876 (1998)
   Google Scholar
• Poggi A, Costa P, Zocchi MR, Moretta L: Phenotypic and functional analysis of CD4+ NKRP1A+ human T lymphocytes. Direct evidence that the NKRP1A molecule is involved in transendothelial migration. Eur. J. Immunol. 27(9), 2345–2350 (1997)
   Google Scholar
• Moser JM, Gibbs J, Jensen PE, Lukacher AE: CD94–NKG2A receptors regulate antiviral CD8+ T cell responses. Nat. Immunol. 3(2), 189–195 (2002)
   Google Scholar
• Lee N, Llano M, Carretero M et al.: HLA-E is a major ligand for the natural killer inhibitoryreceptor CD94/NKG2A. Proc. Natl Acad. Sci. USA 95(9), 5199–5204 (1998)
   Google Scholar
• Bauer S, Groh V, Wu J et al.: Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285(5428), 727–729 (1999)
   Google Scholar
• Van Kaer L: a-galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nat. Rev. Immunol. 5(1), 31–42 (2005).
   Google Scholar